We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Read MoreHide Full Article
Key Takeaways
Roche's phase III first-line advanced breast cancer study of the giredestrant combo missed its key PFS goal.
Roche's combo still showed a numerical PFS improvement, with manageable safety aligned with known profiles.
Roche's giredestrant NDA for second-line breast cancer is under FDA review with a decision due in late 2026.
Roche (RHHBY - Free Report) announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The phase III persevERA Breast Cancer study is evaluating the combo’s efficacy and safety in 992 patients compared to letrozole plus palbociclib in the first-line setting.
Per the data readout, the late-stage study failed to meet its primary endpoint of achieving a statistically significant improvement in progression-free survival (PFS) compared with the standard regimen of letrozole plus palbociclib in the intent-to-treat population. However, the giredestrant combination showed a numerical improvement in PFS.
Safety findings from the study were broadly consistent with expectations. The adverse events observed with the giredestrant and palbociclib combination were manageable and aligned with the known safety profiles of the individual therapies.
Despite the missed primary endpoint, management expressed confidence in the long-term potential of giredestrant across ER-positive breast cancer settings. The company indicated that it continues to see a development path for the candidate, including potential use with CDK4/6 inhibitors in the adjuvant setting, and plans to advance ongoing studies within its broader giredestrant clinical program to identify patient populations that may derive the greatest benefit.
RHHBY’s Breast Cancer Drug Already Under FDA Review
We remind the investors that last month, the FDA accepted Roche’s new drug application (NDA) for giredestrant in combination with everolimus, for the treatment of adult patients with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following progression on prior endocrine therapy. The regulatory body has set a target action date of Dec. 18, 2026.
Per RHHBY, the regimen could become the first and only oral SERD combination available in the post-CDK4/6 inhibitor setting if approved.
In the past six months, Roche’s shares have gained 32.4% compared with the industry’s 20% growth.
Image Source: Zacks Investment Research
The NDA submission for giredestrant is supported by data from the phase III evERA breast cancer study, which showed that giredestrant combined with everolimus significantly improved PFS compared with standard endocrine therapy plus everolimus in patients with ER-positive breast cancer.
Overall survival data showed a favorable trend with further follow-up ongoing, while the regimen demonstrated a manageable safety profile. The evERA study represented the first positive phase III outcome for giredestrant, alongside encouraging results from the phase III lidERA study in early-stage breast cancer, which Roche plans to submit to global regulators, including the FDA, in the near term. The rationale for the lidERA study was supported by earlier neoadjuvant data, including the phase II coopERA study, which showed giredestrant reduced malignant cell proliferation (Ki67 levels) more effectively than an aromatase inhibitor.
Roche stated that the persevERA study represents the first of two phase III studies evaluating giredestrant in the first-line setting. The second study, pionERA, is assessing giredestrant in combination with a physician’s choice of CDK4/6 inhibitor in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer, with results expected in 2027.
More on RHHBY’s Giredestrant
Giredestrant is an investigational, oral, potent next-generation SERD and full antagonist designed to block estrogen and thereby slow or stop the growth of ER-positive breast cancer cells.
Roche is also evaluating giredestrant in an extensive clinical development program in five company-sponsored phase III studies that span multiple treatment settings and lines of therapy.
The successful development of giredestrant will boost RHHBY’s breast cancer franchise, as ER-positive breast cancer accounts for approximately 70% of cases diagnosed.
Over the past 60 days, estimates for USANA Health Sciences’ 2026 earnings per share (EPS) have risen from $1.90 to $2.00. USNA shares have lost 40.8% over the past six months.
USANA Health Sciences’ earnings beat estimates in three of the trailing four quarters and matched once, with the average surprise being 21.92%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.53 to $2.82. CPRX shares have soared 22.8% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ALX Oncology Holdings’ 2026 loss per share have narrowed from $1.21 to 88 cents. ALXO shares have rallied 88.8% over the past six months.
ALX Oncology Holdings’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 12.82%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Key Takeaways
Roche (RHHBY - Free Report) announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The phase III persevERA Breast Cancer study is evaluating the combo’s efficacy and safety in 992 patients compared to letrozole plus palbociclib in the first-line setting.
Per the data readout, the late-stage study failed to meet its primary endpoint of achieving a statistically significant improvement in progression-free survival (PFS) compared with the standard regimen of letrozole plus palbociclib in the intent-to-treat population. However, the giredestrant combination showed a numerical improvement in PFS.
Safety findings from the study were broadly consistent with expectations. The adverse events observed with the giredestrant and palbociclib combination were manageable and aligned with the known safety profiles of the individual therapies.
Despite the missed primary endpoint, management expressed confidence in the long-term potential of giredestrant across ER-positive breast cancer settings. The company indicated that it continues to see a development path for the candidate, including potential use with CDK4/6 inhibitors in the adjuvant setting, and plans to advance ongoing studies within its broader giredestrant clinical program to identify patient populations that may derive the greatest benefit.
RHHBY’s Breast Cancer Drug Already Under FDA Review
We remind the investors that last month, the FDA accepted Roche’s new drug application (NDA) for giredestrant in combination with everolimus, for the treatment of adult patients with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following progression on prior endocrine therapy. The regulatory body has set a target action date of Dec. 18, 2026.
Per RHHBY, the regimen could become the first and only oral SERD combination available in the post-CDK4/6 inhibitor setting if approved.
In the past six months, Roche’s shares have gained 32.4% compared with the industry’s 20% growth.
Image Source: Zacks Investment Research
The NDA submission for giredestrant is supported by data from the phase III evERA breast cancer study, which showed that giredestrant combined with everolimus significantly improved PFS compared with standard endocrine therapy plus everolimus in patients with ER-positive breast cancer.
Overall survival data showed a favorable trend with further follow-up ongoing, while the regimen demonstrated a manageable safety profile. The evERA study represented the first positive phase III outcome for giredestrant, alongside encouraging results from the phase III lidERA study in early-stage breast cancer, which Roche plans to submit to global regulators, including the FDA, in the near term. The rationale for the lidERA study was supported by earlier neoadjuvant data, including the phase II coopERA study, which showed giredestrant reduced malignant cell proliferation (Ki67 levels) more effectively than an aromatase inhibitor.
Roche stated that the persevERA study represents the first of two phase III studies evaluating giredestrant in the first-line setting. The second study, pionERA, is assessing giredestrant in combination with a physician’s choice of CDK4/6 inhibitor in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer, with results expected in 2027.
More on RHHBY’s Giredestrant
Giredestrant is an investigational, oral, potent next-generation SERD and full antagonist designed to block estrogen and thereby slow or stop the growth of ER-positive breast cancer cells.
Roche is also evaluating giredestrant in an extensive clinical development program in five company-sponsored phase III studies that span multiple treatment settings and lines of therapy.
The successful development of giredestrant will boost RHHBY’s breast cancer franchise, as ER-positive breast cancer accounts for approximately 70% of cases diagnosed.
Roche Holding AG Price and Consensus
Roche Holding AG price-consensus-chart | Roche Holding AG Quote
RHHBY’s Zacks Rank and Stocks to Consider
Roche currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are USANA Health Sciences (USNA - Free Report) , Catalyst Pharmaceuticals (CPRX - Free Report) and ALX Oncology Holdings (ALXO - Free Report) . While USNA and CPRX sport a Zacks Rank #1 (Strong Buy) each, ALXO carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for USANA Health Sciences’ 2026 earnings per share (EPS) have risen from $1.90 to $2.00. USNA shares have lost 40.8% over the past six months.
USANA Health Sciences’ earnings beat estimates in three of the trailing four quarters and matched once, with the average surprise being 21.92%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.53 to $2.82. CPRX shares have soared 22.8% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ALX Oncology Holdings’ 2026 loss per share have narrowed from $1.21 to 88 cents. ALXO shares have rallied 88.8% over the past six months.
ALX Oncology Holdings’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 12.82%.